ストックスクリーナーアプリを入手
86.22
0.55%
0.47
アフターアワーズ：
85.68
-0.54
-0.63%
前日終値:
$85.75
開ける：
$85.88
24時間の取引高:
252.82K
Relative Volume:
0.60
時価総額：
$3.00B
収益：
-
当期純損益:
$-91.00M
株価収益率:
-23.49
EPS:
-3.67
ネットキャッシュフロー:
$-74.38M
1週間 パフォーマンス:
+0.69%
1か月 パフォーマンス:
+30.48%
6か月 パフォーマンス:
+74.46%
1年 パフォーマンス:
+92.37%
1日の値動き範囲:
$84.52
$87.00
1週間の範囲:
$83.95
$89.79
52週間の値動き範囲:
$30.82
$95.95
Disc Medicine Inc Stock (IRON) Company Profile
名前
Disc Medicine Inc
セクター
電話
(617) 674-9274
住所
321 ARSENAL STREET, SUITE 101, WATERTOWN
IRON を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
86.22 | 3.21B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-06-11 | 再開されました | Raymond James | Strong Buy |
| 2025-02-27 | 開始されました | TD Cowen | Buy |
| 2024-11-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | 開始されました | Jefferies | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-22 | 開始されました | Wells Fargo | Overweight |
| 2024-04-01 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-17 | 開始されました | Raymond James | Outperform |
| 2023-04-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-04-21 | 開始されました | Stifel | Buy |
| 2023-04-20 | 開始されました | Morgan Stanley | Overweight |
| 2023-03-23 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-28 | 開始されました | SVB Securities | Outperform |
すべてを表示
Disc Medicine Inc (IRON) 最新ニュース
Morgan Stanley Issues Positive Forecast for Disc Medicine (NASDAQ:IRON) Stock Price - MarketBeat
Disc Medicine stock reiterated Strong Buy at Raymond James on DISC-0974 potential - Investing.com
Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail
Disc Medicine to Participate in Upcoming Investor Conferences - Enidnews.com
Disc Medicine (NASDAQ: IRON) to appear at Guggenheim, Stifel, Jefferies; live webcasts - Stock Titan
Is Disc Medicine Inc. stock trading near support levelsJuly 2025 Update & Weekly Stock Breakout Alerts - newser.com
Can Disc Medicine Inc. stock weather global recession2025 Earnings Impact & Weekly High Momentum Picks - newser.com
Is Disc Medicine Inc. stock in correction or buying zone2025 Technical Overview & Risk Controlled Swing Trade Alerts - newser.com
Why Disc Medicine Inc. stock is considered a top pick2025 Year in Review & Low Risk High Reward Trade Ideas - newser.com
Disc Medicine, Inc. (NASDAQ:IRON) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What valuation multiples suggest for Disc Medicine Inc. stockJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Applying Wyckoff theory to Disc Medicine Inc. stock2025 Sector Review & Stock Portfolio Risk Control - newser.com
WilmerHale Advises Underwriters in $287.5 Million Public Offering of Disc Medicine - WilmerHale
IRON Stock: Morgan Stanley Raises Price Target to $115 | IRON St - GuruFocus
Morgan Stanley Raises Price Target on Disc Medicine to $115 From $90, Keeps Overweight Rating - MarketScreener
Chronic Kidney Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Jiangsu HengRui, Disc Medicine, 3SBio, Kind Pharma, Jiangsu Hansoh Pharm - Barchart.com
Disc Medicine (IRON): Evaluating Valuation After New Clinical Trial Plans and FDA Recognition Boost Pipeline Momentum - Yahoo Finance
Disc Medicine planning trial of iron overload treatment for sickle cell - Sickle Cell Disease News
Aug Chart Watch: Why Disc Medicine Inc. stock is considered a top pickQuarterly Earnings Summary & Daily Entry Point Trade Alerts - Fundação Cultural do Pará
Top chart patterns to watch in Disc Medicine Inc.July 2025 Breakouts & Consistent Profit Focused Trading Strategies - newser.com
Will Disc Medicine Inc. stock maintain growth storyJuly 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
How Disc Medicine Inc. stock performs in interest rate cycles2025 AllTime Highs & Weekly Top Gainers Trade List - newser.com
Disc Medicine’s APOLLO Study: A Potential Game-Changer for EPP and XLP Treatment - TipRanks
Disc Medicine’s Promising Phase 2 Study on DISC-3405 for Polycythemia Vera - TipRanks
Disc Medicine’s New Study on DISC-3405: A Potential Breakthrough for Sickle Cell Disease - TipRanks
What Makes Disc Medicine, Inc. (IRON) a Strong Momentum Stock: Buy Now? - sharewise.com
Disc Medicine’s Promising Anemia Treatment Study: Key Insights for Investors - TipRanks
Disc Medicine’s Promising EPP Treatment Study: Key Updates and Market Impact - TipRanks
Disc Medicine Inc (IRON) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):